VU6067416 is an indazole derivative which acts as an agonist for the 5-HT2 family of serotonin receptors. It is a potent full agonist at 5-HT2B, and has slightly lower affinity and partial agonist effects at 5-HT2A and 5-HT2C,[1] though some related compounds have improved selectivity for 5-HT2A.[2]

VU6067416
Identifiers
  • 3-(1,2,5,6-tetrahydropyridin-3-yl)-5-bromo-1H-indazole
PubChem CID
Chemical and physical data
FormulaC12H12BrN3
Molar mass278.153 g·mol−1
3D model (JSmol)
  • Brc1cc2c(n[NH]c2cc1)C=1CNCCC=1
  • InChI=1S/C12H12BrN3/c13-9-3-4-11-10(6-9)12(16-15-11)8-2-1-5-14-7-8/h2-4,6,14H,1,5,7H2,(H,15,16)
  • Key:OZAHEVLLVSEENQ-UHFFFAOYSA-N

See also

edit

References

edit
  1. ^ Jayakodiarachchi N, Maurer MA, Schultz DC, Dodd CJ, Thompson Gray A, Cho HP, et al. (January 2024). "Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists". ACS Medicinal Chemistry Letters. doi:10.1021/acsmedchemlett.3c00566. PMC 10860182.
  2. ^ Kargbo RB (November 2023). "Small-Molecule Heterocyclic Compounds: Gq-Biased Agonists for the 5-HT2A Receptor in Neuropsychiatric Treatment". ACS Medicinal Chemistry Letters. 14 (11): 1498–1500. doi:10.1021/acsmedchemlett.3c00444. PMC 10641896. PMID 37974947.